Bimekizumab, sold under the brand name Bimzelx, is the psoriasis drug that is rewriting what doctors and patients expect from treatment. FDA approved in October 2023, this biologic achieved something no previous therapy had managed at scale: roughly 60 to 68 percent of patients reached complete skin clearance — a PASI 100 score — within just 16 weeks. That is not a marginal improvement over older biologics. It is a different category of result, and it is forcing dermatologists to reconsider what “treatment success” actually means.
For the millions of people living with moderate-to-severe plaque psoriasis, this shift matters beyond cosmetics. Psoriasis is a systemic inflammatory disease with well-documented links to cardiovascular risk, metabolic syndrome, depression, and emerging research into neuroinflammation. When a drug clears skin this effectively and sustains that clearance for years, the downstream effects on quality of life and comorbid disease burden are significant. Five-year data presented at the American Academy of Dermatology annual meeting in 2025 showed that 67.7 percent of patients maintained complete clearance and 84.9 percent maintained PASI 90 at the five-year mark. This article covers how bimekizumab works, what the clinical data actually shows, the oral drugs coming up behind it, and what all of this means for people managing chronic inflammatory conditions.
Table of Contents
- Why Is This Psoriasis Drug So Effective That It’s Changing the Standard of Care?
- What the Safety Profile Looks Like Over Five Years
- Oral Alternatives That Could Replace Injections Entirely
- How Oral TYK2 Inhibitors Compare to Biologics
- What This Means for Pediatric and Young Patients
- The Brain Health Connection — Why a Dementia Site Covers Psoriasis
- Where Psoriasis Treatment Is Headed
- Conclusion
- Frequently Asked Questions
Why Is This Psoriasis Drug So Effective That It’s Changing the Standard of Care?
Bimekizumab is the first biologic designed to selectively inhibit both interleukin-17A and interleukin-17F. Previous IL-17 inhibitors like secukinumab and ixekizumab targeted only IL-17A, leaving IL-17F to continue driving inflammation. The dual blockade is not a theoretical advantage — it showed up clearly in head-to-head trials. A study published in the new England Journal of Medicine demonstrated that bimekizumab produced superior skin clearance compared to secukinumab, which had been among the top-performing biologics on the market. The speed of response is another factor that sets this drug apart. More than 7 in 10 patients achieved PASI 75 at just week 4 after a single 320 mg dose.
For someone who has been cycling through topical steroids, phototherapy, and older systemics for years, visible improvement in a month is not just clinically meaningful — it changes how they relate to treatment. Previous biologics often required 12 to 16 weeks before patients could assess whether they were working. With bimekizumab, the signal comes fast enough to keep people engaged with their treatment plan. What makes dermatologists particularly attentive is durability. Short-term clearance data can look impressive in trials and then fade in practice as patients develop antibodies or lose response. The BE BRIGHT open-label extension tracked 153 patients over five years, and the results held: 67.7 percent still at PASI 100 and 84.9 percent at PASI 90 at year five. That kind of sustained efficacy is what transforms a drug from a good option into a new standard of care.
What the Safety Profile Looks Like Over Five Years
No drug this potent comes without tradeoffs. Blocking IL-17A and IL-17F simultaneously suppresses part of the immune system’s frontline defense against certain infections, particularly fungal infections of the mucous membranes. The most commonly reported adverse events over five years of bimekizumab use were nasopharyngitis at 9.7 per 100 patient-years, oral candidiasis at 7.6 per 100 patient-years, and upper respiratory tract infection at 5.8 per 100 patient-years. Oral candidiasis — thrush — is the side effect that gets the most discussion among prescribers. A rate of 7.6 per 100 patient-years means it is not rare, and for some patients it becomes a recurring nuisance that requires antifungal treatment.
However, candidiasis episodes were generally mild to moderate and manageable, and they did not lead to significant rates of treatment discontinuation in the extension studies. dermatologists who prescribe bimekizumab typically counsel patients about this risk upfront and may recommend prophylactic measures for those with a history of fungal infections. It is worth noting what did not show up in the long-term data. Serious cardiovascular events, malignancies, and inflammatory bowel disease — concerns that have shadowed some other IL-17 inhibitors — did not emerge as signals over five years. However, if you have active inflammatory bowel disease, most dermatologists will still avoid IL-17 class drugs entirely and opt for IL-23 inhibitors instead. The safety profile is reassuring for the broader population, but individual risk factors still matter.
Oral Alternatives That Could Replace Injections Entirely
While bimekizumab is setting the bar for injectable biologics, a parallel revolution is happening in oral treatments. Icotrokinra, developed by Johnson & Johnson, is a first-in-class oral peptide that targets the IL-23 receptor. If that description sounds unremarkable, consider what it means: a pill that does what currently requires an injection. J&J has submitted a new drug application based on four Phase 3 ICONIC trials covering patients aged 12 and older. The one-year data from the ICONIC-LEAD trial, presented at the European Academy of Dermatology and Venereology congress in 2025, showed approximately 90 percent of patients achieving PASI 75 at week 52, with 84 percent maintaining PASI 90 and 82 percent sustaining clear or almost clear skin. Among adolescents, 100 percent achieved PASI 75 by week 32 and maintained it through week 52.
Safety data showed rates of serious infections and malignancy under 1 percent, with no cases of active tuberculosis reported. If icotrokinra reaches the market, it would change the conversation for patients who refuse or cannot tolerate injections. There is a meaningful subset of people with moderate-to-severe psoriasis who decline biologic therapy specifically because of needle aversion or the burden of injection schedules. An oral drug with biologic-level efficacy removes that barrier. However, oral peptides come with their own challenges — absorption variability, food interaction requirements, and the discipline of daily dosing versus a once-monthly injection. The convenience calculus is not as straightforward as “pills beat needles.”.
How Oral TYK2 Inhibitors Compare to Biologics
Deucravacitinib, marketed as Sotyktu by Bristol Myers Squibb, was FDA approved in September 2022 as the first-in-class oral TYK2 inhibitor for moderate-to-severe plaque psoriasis. It represented the first credible oral alternative that was not a traditional immunosuppressant like methotrexate or cyclosporine. Its efficacy is solid but does not match bimekizumab’s clearance rates — a tradeoff patients and dermatologists weigh against the convenience of oral dosing. The FDA was expected to decide on an expanded indication for psoriatic arthritis by March 6, 2026, which would make deucravacitinib more attractive for patients dealing with both skin and joint disease. Coming behind it is zasocitinib from Takeda, a next-generation oral TYK2 inhibitor that met all primary endpoints in two pivotal Phase 3 trials.
Takeda plans to seek FDA approval in 2026. The question dermatologists are watching is whether second-generation TYK2 inhibitors can close the efficacy gap with injectable biologics while maintaining the convenience advantage of once-daily oral dosing. The honest comparison is this: if maximum skin clearance is the priority, bimekizumab currently wins. If a patient values oral dosing, has mild-to-moderate joint symptoms, or has comorbidities that make IL-17 blockade less appropriate, the TYK2 inhibitors offer a meaningful alternative. The best psoriasis drug is the one a patient will actually take consistently, and for some people, that means a pill rather than an injection.
What This Means for Pediatric and Young Patients
One of the most underserved populations in psoriasis treatment has been children. Most biologics were approved only for adults, leaving pediatric dermatologists with limited tools — primarily topical steroids with well-known long-term side effects. The landscape is shifting. Roflumilast cream, sold as Zoryve, already offered a non-steroidal topical option, and the FDA has accepted a supplemental new drug application to expand its use to children ages 2 to 5. If approved, it would become the first topical PDE4 inhibitor available for children that young. Icotrokinra’s trial program included patients as young as 12, and the adolescent results were striking — complete PASI 75 response by week 32 in every participant.
For families managing a teenager’s psoriasis through the already difficult years of adolescence, an oral medication with that level of efficacy could be transformative. However, long-term safety data in growing adolescents remains limited, and most dermatologists will want to see post-marketing surveillance before broadly prescribing newer agents in this age group. Tapinarof, another non-steroidal topical, is also advancing as a corticosteroid alternative, giving clinicians more options for mild-to-moderate disease where systemic therapy is not warranted. Parents should be aware that psoriasis treatment in children still requires careful risk-benefit discussions. A drug that is safe and effective in adult trials does not automatically carry the same profile in a developing immune system. The expansion of approved options is unquestionably positive, but the conservative approach of starting with the least systemic therapy and escalating only when needed remains sound.
The Brain Health Connection — Why a Dementia Site Covers Psoriasis
Psoriasis is not a skin-only disease. Chronic systemic inflammation drives the plaques on the skin, but the same inflammatory pathways — including elevated IL-17 and IL-23 — have been implicated in neuroinflammation and blood-brain barrier disruption. Epidemiological studies have found that people with severe psoriasis have a modestly elevated risk of cognitive decline and dementia compared to age-matched controls. The mechanisms likely involve chronic vascular inflammation, increased rates of metabolic syndrome and diabetes in psoriasis patients, and direct effects of circulating cytokines on brain microvasculature.
This is why effective psoriasis treatment matters beyond the skin. If drugs like bimekizumab can durably suppress systemic inflammation, the downstream benefits may extend to cardiovascular health, metabolic function, and potentially neuroprotection. It is too early to claim that treating psoriasis prevents dementia — that research has not been done in a controlled way. But reducing the total inflammatory burden in someone who will live with a chronic autoimmune condition for decades is, at minimum, a plausible strategy for protecting long-term brain health.
Where Psoriasis Treatment Is Headed
The next two to three years will bring more competition and more choices. Icotrokinra and zasocitinib are both expected to seek or receive FDA decisions in 2026. If oral drugs can approach injectable biologic efficacy, the treatment algorithm will shift dramatically — dermatologists may start offering oral options first and reserve injectables for non-responders, reversing the current hierarchy.
The broader implication is that complete or near-complete skin clearance is becoming the expected outcome rather than the aspirational one. When 85 to 90 percent of patients on the best available drug achieve clear or almost clear skin, anything less starts to feel inadequate. That pressure will push the entire field forward, benefiting patients who today are still undertreated with older therapies that deliver PASI 75 as a ceiling rather than a floor.
Conclusion
Bimekizumab has established a new benchmark for psoriasis treatment, with roughly two-thirds of patients achieving and maintaining complete skin clearance over five years. Behind it, oral therapies like icotrokinra, deucravacitinib, and zasocitinib are working to deliver comparable results without injections. Non-steroidal topicals are expanding access to younger patients.
Taken together, these advances represent the most significant shift in psoriasis care in a generation. For anyone living with moderate-to-severe psoriasis — or caring for someone who is — the practical message is that settling for partial improvement is no longer necessary. Talk to a dermatologist about whether newer therapies are appropriate, particularly if current treatment leaves significant disease burden. And for those concerned about the long-term health consequences of chronic inflammation, including its potential effects on the brain, effective disease control is one of the most concrete steps available.
Frequently Asked Questions
What is bimekizumab and how is it different from older psoriasis biologics?
Bimekizumab (Bimzelx) is the first biologic that selectively blocks both IL-17A and IL-17F. Older IL-17 inhibitors like secukinumab only blocked IL-17A. This dual inhibition produces higher rates of complete skin clearance — approximately 60 to 68 percent PASI 100 at 16 weeks, compared to lower rates with single-target drugs.
Is there an oral drug for psoriasis that works as well as biologics?
Icotrokinra, an oral IL-23 receptor inhibitor developed by Johnson & Johnson, has shown results approaching biologic-level efficacy in Phase 3 trials, with approximately 90 percent of patients achieving PASI 75 at one year. It is under FDA review but not yet approved. Currently available oral options like deucravacitinib (Sotyktu) are effective but generally do not match the highest-performing injectable biologics.
What are the main side effects of bimekizumab?
Over five years of study, the most common adverse events were nasopharyngitis (common cold symptoms), oral candidiasis (thrush), and upper respiratory tract infections. Oral candidiasis occurred at a rate of 7.6 per 100 patient-years and is the side effect most specific to this drug class. Episodes were generally mild to moderate.
Can children take these new psoriasis drugs?
Options are expanding. Roflumilast cream (Zoryve) may soon be approved for children as young as 2, and icotrokinra’s trials included adolescents aged 12 and older with strong results. However, most newer biologics and oral systemics are currently approved only for adults, and long-term pediatric safety data remains limited.
Does psoriasis affect brain health?
Research suggests that people with severe psoriasis have a modestly elevated risk of cognitive decline, likely driven by chronic systemic inflammation, vascular damage, and higher rates of metabolic comorbidities. Effectively treating psoriasis may help reduce this inflammatory burden, though no controlled studies have yet proven that psoriasis treatment directly prevents dementia.
